Madelung’s disease with alcoholic liver disease and acute kidney injury: A case report

BACKGROUND Madelung’s disease(MD)is a rare disorder of lipid metabolism,characterized by the growth of unencapsulated masses of adipose tissue symmetrically deposited around the neck,shoulders,or other sites around the body.Its pathological mechanism is not yet known.One of the most common comorbidities in MD patients is liver disease,especially chronic alcoholic liver disease(CALD);however,no reports exist of acute kidney injury(AKI)with MD.CASE SUMMARY We report a 60-year-old man who presented with complaint of edema in the lower limbs that had persisted for 3 d.Physical examination showed subcutaneous masses around the neck,and history-taking revealed the masses to have been present for 2 years and long-term heavy drinking.Considering the clinical symptoms,along with various laboratory test results and imaging characteristics,a diagnosis was made of MD with acute exacerbation of CALD and AKI.The patient was treated with liver function protection and traditional Chinese medicine,without surgical intervention.He was advised to quit drinking.After 10 d,the edema had subsided,renal function indicators returned to normal,liver function significantly improved,and size of subcutaneous masses remained stable.CONCLUSION In MD,concomitant liver or kidney complications are possible and monitoring of liver and kidney functions can be beneficial.

Clinical efficacy analysis of mesenchymal stem cell therapy in patients with COVID-19:A systematic review

BACKGROUND Currently,ongoing trials of mesenchymal stem cells(MSC)therapies for coronavirus disease 2019(COVID-19)have been reported.AIM In this study,we investigated whether MSCs have therapeutic efficacy in novel COVID-19 patients.METHODS Search terms included stem cell,MSC,umbilical cord blood,novel coronavirus,severe acute respiratory syndrome coronavirus-2 and COVID-19,applied to Pub Med,the Cochrane Controlled Trials Register,EMBASE and Web of Science.RESULTS A total of 13 eligible clinical trials met our inclusion criteria with a total of 548 patients.The analysis showed no significant decrease in C-reactive protein(CRP)levels after stem cell therapy(P=0.11).A reduction of D-dimer levels was also not observed in patients after stem cell administration(P=0.82).Furthermore,interleukin 6(IL-6)demonstrated no decrease after stem cell therapy(P=0.45).Finally,we investigated the overall survival(OS)rate after stem cell therapy in COVID-19 patients.There was a significant improvement in OS after stem cell therapy;the OS of enrolled patients who received stem cell therapy was 90.3%,whereas that of the control group was 79.8%(P=0.02).CONCLUSION Overall,our analysis suggests that while MSC therapy for COVID-19 patients does not significantly decrease inflammatory markers such as CRP,D-dimer and IL-6,OS is improved.

Relative bioavailability and pharmacokinetic comparison of two different enteric formulations of omeprazole

In order to comply with the requirements for a drug listed in China, the study was developed to compare the pharmacokinetics and relative bioavailability of two different enteric formulations of omeprazole (OPZ) in healthy Chinese subjects. A total of 32 volunteers participated in the study. Plasma concentrations were analyzed by non- stereospecific liquid chromatography/tandem mass spectrometric (LC-MS/MS) method. After administration of a single 40-mg dose of the two OPZ formulations, the comparative bioavailability was assessed by calculating individual AUC0-t (the area under the concentration-time curve from time zero to the last measurable concentration), AUC0-∞ (the area under the concentration-time curve extrapolated to infinity), Cmax (the maximum observed concentration), and Tpeak (the time to Cmax) values of OPZ, 5-hydroxyomeprazole (OH-OPZ), and omeprazole sulfone (OPZ-SFN), respectively. The 90% confidence intervals (CIs) of AUC0-t, AUC0-∞, and Cmax were 85.4%-99.0%/88.8%-98.6%/87.6%-99.4%, 85.5%-99.2%/89.0%-98.6%/88.5%-101.3%, and 72.3%-87.6%/79.6%-91.1%/88.4%-99.1% for OPZ/OH-OPZ/ OPZ-SFN, respectively, and Tpeak values did not differ significantly. In this study, the test formulation of OPZ in fasting healthy Chinese male volunteers met the Chinese bioequivalance standard to the reference formulation based on AUC, Cmax, and Tpeak.